Sutro Biopharma, INC Schedule 13G passive stakes

Point72 Asset Management, L.P., along with related entities and Steven A. Cohen, has reported beneficial ownership of 1.4% of Sutro Biopharma, Inc.'s common stock as of June 30, 2026.

Kynam Capital Management, LP has filed a Schedule 13G reporting a 5.27% beneficial ownership stake in Sutro Biopharma, Inc.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,069,519 shares, representing 6.5% of Sutro Biopharma, Inc.'s common stock as of March 31, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 5.7% beneficial ownership stake in Sutro Biopharma, Inc. via a Schedule 13G filing.

Millennium Management LLC and Israel A. Englander have filed a Schedule 13G reporting a 1.3% beneficial ownership stake in Sutro Biopharma, Inc.

Perceptive Advisors LLC and Joseph Edelman have reported a 5.4% beneficial ownership stake in Sutro Biopharma, Inc. via a Schedule 13G filing.

A group of entities associated with Biotechnology Value Fund and Mark N. Lampert reported beneficial ownership of 7.6% of Sutro Biopharma, Inc.'s common stock.

Suvretta Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Sutro Biopharma, Inc., now holding 0% of the common stock.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported a 0% beneficial ownership in Sutro Biopharma, Inc., indicating a full divestment or reduction below the 5% reporting threshold.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 8.8% of Sutro Biopharma, Inc.'s common stock.

Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have disclosed a combined beneficial ownership of 7.77% in Sutro Biopharma, Inc. common stock.

RA Capital Management and its affiliates have fully divested their beneficial ownership in Sutro Biopharma, Inc., reducing their stake to 0.0%.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, confirming a 7.7% beneficial ownership stake in Sutro Biopharma, Inc.

The Vanguard Group reported a 4.87% beneficial ownership stake in Sutro Biopharma Inc., holding 4,115,250 shares of common stock as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, reporting a 2.5% beneficial ownership stake in Sutro Biopharma, Inc. as a passive investor.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a beneficial ownership of 5.6% of Sutro Biopharma, Inc.'s Common Stock.

Kynam Capital Management, LP, along with its general partner Kynam Capital Management GP, LLC, and Yue Tang, has reported a passive beneficial ownership of 6.44% in Sutro Biopharma, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in Sutro Biopharma, Inc. as of March 31, 2025, indicating a passive investment.

RA Capital Management, L.P. and its affiliates have disclosed a passive beneficial ownership of 5.3% of Sutro Biopharma, Inc.'s common stock.